https://orcid.org/0000-0003-3479-4550
Figures & data
Figure 1 PRISMA flowchart. *Five studies provided data and were included in more than one review. Adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Creative Commons.
Table 1 Characteristics of the Included Studies Providing Data for Advanced Liver Cancer
Figure 2 Evidence map for ACD in advanced liver cancer. The size of each dot represents the number of studies that address the intervention/outcome relationship. The color of each dot represents the methodological design of the study group.
Figure 3 Summary of the direction of the effect for each study and outcome in patients with advanced liver cancer.
Abbreviations: OBS, observational study; RCT, randomized control trial; SR, systematic review; CT, chemotherapy; BIO/TT, biological/target therapy; IT, immunotherapy; OS, Overall Survival. PFS, Progression-free survival; mo, Months; FI, Favors intervention (ACD); ND, No difference; FC, Favors comparison (BSC/placebo); NR, Not reported.
Table 2 Characteristics of the Included Studies on Advanced Gallbladder and Bile Duct Cancers
Figure 4 Evidence map for ACD in advanced gallbladder/bile duct cancers. The size of each dot represents the number of studies that address the intervention/outcome relationship. The color of each dot represents the methodological design of the study group.
Figure 5 Summary of the direction of the effect for each study and outcome in patients with advanced gallbladder and bile duct cancers.
Abbreviations: OBS, observational study; RCT, randomized control trial; SR, systematic review; CT, chemotherapy; BIO/TT, biological/target therapy; IT, immunotherapy; OS, Overall Survival; PFS, Progression-free survival; mo, Months; FI, Favors intervention (ACD); ND, No difference; FC, Favors comparison (BSC/placebo); NR, Not reported.
